[1] 李兰娟,段钟平.肝衰竭诊治指南(2012年版).中华移植杂志 (电子版),2013,7:48-56.
[2] Xie GJ,Zhang HY,Chen Q,et al.Changing etiologies and outcome of liver failure in southwest China.Virol J,2016,13:89.
[3] Fernandez J,Acevedo J,Weist R,et al.Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis.Gut,2018,67:1870-1880
[4] 胡世芸, 陈妍雯, 潘宗琴, 等. 我国肝衰竭医院感染危险因素的Meta分析. 遵义医学院学报, 2014, 37:520-528.
[5] 陈珍晶,陈瑜,等.肝硬化患者无菌腹水中真菌DNA的检测及易位研究.中国微生态学杂志,2012,24:481-484
[6] Sarin SK,Kedarisetty CK,Abbas Z,et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014,.Hepatol Int,2014,8:453-471
[7] Lilly EA,Lkeh M,Nash EE,et al.Immune protection against lethal fungal-bacterial intra-abdominal infections,mBiO,2018,9:e01472-17
[8] 蔡晓娟, 沈毅, 朱晓红, 等. 整合终末期肝病模型在慢加急性肝功能衰竭预后判断及治疗中的应用. 中华实验和临床感染病杂志(电子版), 2018, 12:446-452.
[9] Cai J , Zhang M , Han T,et al. Characteristics of infection and its impact on short-term outcome in patients with acute-on-chronic liver failure. Medicine, 2017, 96:e8057.
[10] Hassan EA,Abd El-Rehim AS,Hassany SM,et al. Fungal infection in patients with end -stage liver disease: low frequency or low index of suspicion. Int J Infect Dis,2014,23: 69 -74.
[11] 王宇,胡瑾华,等. 肝衰竭合并真菌感染发病特点及预后因素影像.临床肝胆病杂志,2019,35:419-423
[12] Lin YY,Shiau S,Fang CT. Risk factors for invasive Cryptococcus neoformans diseases: a case-control study. PLoS One,2015,10: e0119090.
[13] 王志炜,孟春萍,沈华江,等. 重型肝炎患者医院感染病原学特点及相关因素分析. 中华医院感染学杂志,2018,28: 535 -537,542
[14] Bajaj JS,Liu EJ, Kheradman R,et al.Fungal dysbiosis in cirrhosis.Gut,2018,67:1146-1154.
[15] Matsubara VH, Bandara HM,Mayer MP,et al. Probiotics as antifungals in mucosal candidiasis. Clin Infect Dis,2016,62: 1143 -1153.
[16] 曾跃斌, 李铭航, 王迪, 等. 白念珠菌359株分离鉴定及其对5种抗真菌药物的敏感性分析. 中国药物与临床, 2018, 18:166-168.
[17] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组, 李兰娟, 等. 肝衰竭诊治指南(2018年版). 实用肝脏病杂志, 2019.
[18] 聂青和.肝衰竭综合治疗进展.实用肝脏病杂志,2013,1:17-19
[19] Gustot T , Maillart E , Bocci M , et al. Invasive aspergillosis in patients with severe alcoholic hepatitis. J Hepatol, 2014, 60:267-274.
[20] 陈妍雯, 胡世芸, 潘宗琴, 等. 我国肝衰竭真菌感染危险因素荟萃分析. 中华医院感染学杂志, 2014:2493-2496.
[21] 张志成,张骏,谭荣欣,等.肝衰竭合并真菌感染临床分析.江西医药, 2011, 46:247-249.
[22] 刘俊杰,焦秋红,等.96例肝衰竭合并真菌感染耐药性分析.肝脏,2013,18:793-794
[23] 陆晖, 李孟英, 谭可平,等. 不同真菌感染对肝衰竭患者病情及预后影响的研究. 肝脏, 2017:332-334.
[24] 徐媛, 陈敏, 廖万清.中国侵袭性曲霉菌病流行病学现状.中国真菌学杂志, 2018, 13: 57-60.
[25] 郭宪立, 宋宁, 刘跃, 等 2015慢性肺曲霉菌病诊断和治疗临床指南解读. 临床荟萃, 2016, 31:325-331.
[26] 陈黎雄, 陈德昌,等. IDSA 2016年版《曲霉菌感染临床诊疗指南》更新剖析. 中国医刊, 2018, 53:21-24.
[27] 中国侵袭性真菌感染工作组.血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第五次修订版),中华内科杂志,2017,56:453-459.
[28] 印为武, 彭卫,戚继荣,等. 侵袭性肺曲霉菌感染MSCT特征及对预后的评价. 中国CT和MRI杂志, 2017,15:58-61.
[29] Rogers TR,Slavin MA,Donnelly JP.Antifungal prophylaxis during treatment for haematological malignancies:are we there yet?.Br J Haematol,2011,153:681-697.
[30] Liu Q,lin R,Sun J,et al.Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis.Biol Boold Marrow Transplant,2014,20:1198-1203.
[31] Maschmeyer G,Heinz WJ,Hertenstein B,et al.Immediate versus deferred empirical antifungal(IDEA) therapy in high-risk patients with febrile neutropenia:a randomized double-blind,placebo-controlled,multicenter study.Eur J Chin Microbiol Infect Dis,2013,32:679-689.
[32] Malhotra P,Makkar A,Guru Murthy GS,et al.Empirical amphotericin B therapy on day 4 or day 8 of febrile neutropenia.Mycoses,2014,57:110-115.
[33] Nucci M,Nouer SA,Cappone D,et al.Early diagnosis of invasive pulmonary aspergillosis in hemotologic patients:an opportunity to improve the outcome.Heamatologica,2013,98:1657-1660. |
